Cargando…
Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
Cancer is a multifactorial disease with increasing incidence. There are more than 100 different cancer types, defined by location, cell of origin, and genomic alterations that influence oncogenesis and therapeutic response. This heterogeneity between tumors of different patients and also the heterog...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072767/ https://www.ncbi.nlm.nih.gov/pubmed/33920536 http://dx.doi.org/10.3390/cells10040928 |
_version_ | 1783683981261144064 |
---|---|
author | Pfohl, Ulrike Pflaume, Alina Regenbrecht, Manuela Finkler, Sabine Graf Adelmann, Quirin Reinhard, Christoph Regenbrecht, Christian R. A. Wedeken, Lena |
author_facet | Pfohl, Ulrike Pflaume, Alina Regenbrecht, Manuela Finkler, Sabine Graf Adelmann, Quirin Reinhard, Christoph Regenbrecht, Christian R. A. Wedeken, Lena |
author_sort | Pfohl, Ulrike |
collection | PubMed |
description | Cancer is a multifactorial disease with increasing incidence. There are more than 100 different cancer types, defined by location, cell of origin, and genomic alterations that influence oncogenesis and therapeutic response. This heterogeneity between tumors of different patients and also the heterogeneity within the same patient’s tumor pose an enormous challenge to cancer treatment. In this review, we explore tumor heterogeneity on the longitudinal and the latitudinal axis, reviewing current and future approaches to study this heterogeneity and their potential to support oncologists in tailoring a patient’s treatment regimen. We highlight how the ideal of precision oncology is reaching far beyond the knowledge of genetic variants to inform clinical practice and discuss the technologies and strategies already available to improve our understanding and management of heterogeneity in cancer treatment. We will focus on integrating multi-omics technologies with suitable in vitro models and their proficiency in mimicking endogenous tumor heterogeneity. |
format | Online Article Text |
id | pubmed-8072767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80727672021-04-27 Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed Pfohl, Ulrike Pflaume, Alina Regenbrecht, Manuela Finkler, Sabine Graf Adelmann, Quirin Reinhard, Christoph Regenbrecht, Christian R. A. Wedeken, Lena Cells Review Cancer is a multifactorial disease with increasing incidence. There are more than 100 different cancer types, defined by location, cell of origin, and genomic alterations that influence oncogenesis and therapeutic response. This heterogeneity between tumors of different patients and also the heterogeneity within the same patient’s tumor pose an enormous challenge to cancer treatment. In this review, we explore tumor heterogeneity on the longitudinal and the latitudinal axis, reviewing current and future approaches to study this heterogeneity and their potential to support oncologists in tailoring a patient’s treatment regimen. We highlight how the ideal of precision oncology is reaching far beyond the knowledge of genetic variants to inform clinical practice and discuss the technologies and strategies already available to improve our understanding and management of heterogeneity in cancer treatment. We will focus on integrating multi-omics technologies with suitable in vitro models and their proficiency in mimicking endogenous tumor heterogeneity. MDPI 2021-04-17 /pmc/articles/PMC8072767/ /pubmed/33920536 http://dx.doi.org/10.3390/cells10040928 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pfohl, Ulrike Pflaume, Alina Regenbrecht, Manuela Finkler, Sabine Graf Adelmann, Quirin Reinhard, Christoph Regenbrecht, Christian R. A. Wedeken, Lena Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title | Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title_full | Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title_fullStr | Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title_full_unstemmed | Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title_short | Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed |
title_sort | precision oncology beyond genomics: the future is here—it is just not evenly distributed |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072767/ https://www.ncbi.nlm.nih.gov/pubmed/33920536 http://dx.doi.org/10.3390/cells10040928 |
work_keys_str_mv | AT pfohlulrike precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT pflaumealina precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT regenbrechtmanuela precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT finklersabine precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT grafadelmannquirin precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT reinhardchristoph precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT regenbrechtchristianra precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed AT wedekenlena precisiononcologybeyondgenomicsthefutureishereitisjustnotevenlydistributed |